http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RS-50398-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_132aa5ddba376cda52c2bedb26765245 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7076 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70 |
| filingDate | 2002-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67d4b069c42ebb24a09f992f9aa81ff9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a18ca6495fff5f1575405470cb427fe http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_84abc477f88992602a4ad3ac5697a0e0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d4c4f85844b87cae9dd650a3b98145e |
| publicationDate | 2009-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RS-50398-B |
| titleOfInvention | ORAL FLUDARA HIGH PURITY FORMULATIONS WITH FAST RELEASE OF THE ACTIVE INGREDIENT |
| abstract | Fast-release tablet formulation consisting of 1 to 100 mg of fludar active ingredient in purity> 99.19%, together with, Lactose monohydrate, Colloidal silicon dioxide, Microcrystalline cellulose (avicel), Croscaramellose-Na (sodium carboxymethyl cellulose) and stearate, characterized in that the contaminants in the fluda do not exceed the following percentages: 0.02% 2-Fluoro-9- (ß-D-arabinofuranosyl) -9H-purin-6-amine, 0.12% 6-Amino-9 (5-O-phosphono-ß-D-arabinofuranosyl) -9H-purin-2-ol, 0.02% 2-Fluoro-9H-purin-6-amine, 0.02% 6-Amino-9H-purine- 2-ol, 0.05% 2-Fluoro-9- (5-O-phosphono-ß-D-ribofuranosyl) -9H-purin-6-amine, 0.1% o 9- (3,5-O- diphosphono-ß-D-arabinofuranosyl) -2-fluoro-9H-purin-6-amine, 0.1% 9- (2,5-O-diphosphono-ß-D-arabinofuranosyl) -2-fluoro-9H-purine -6-amine, 0.02% 2-Fluoro-9- (5-O-phosphono-ß-D-arabinofuranosyl) -9H-purin-6-amine, 0.06% 2-Ethoxy-9- (5- O-phosphono-ß-D-arabinofuranosyl) -9H-purin-6-amine, 0.02% 2- (6-Amino-9H-purin-2-yl) -9- (5-O-phosphono-ß- D-arabinofuranosyl) -9H-purin-6-amine and 0.0 1-bis [2- (6-amino-2-fluoro-9H-purin-9-yl) -5-deoxy-α-D-arabinofuranos-5-yl] -phosphate, 0.1% 9- (2- Chloro-2-deoxy-5-phosphono-ß-D-arabinofuranosyl) -2-fluoro-9H-purin-6 amine and 0.1% 9- (2,5-Anhydro-ß-D-arabinofuranosyl) -2- fluoro-9H-purine-6-amine. The application contains 1 independent and 10 dependent patent claims |
| priorityDate | 2001-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 47.